The recently authorized emergency use of remdesivir by the US Food and Drug Administration (FDA) for patients hospitalized with severe confirmed or suspected COVID-19 represents an important step forward for reducing morbidity during the pandemic. However, while remdesivir was able to significantly accelerate recovery in the double-blind placebo-controlled NIAID ACTT-1 trial, approximately 8% of treated […]